Micronized purified flavonoid fraction in pretreating CABG patients

Texas Heart Institute Journal

Volumn 37, Issue 2, 2010, Pages 172-177

  Srilak, Mustafa ^a   Akar, A Ruchan ^a   Eryilmaz, Sadik ^a   Cetinkanat, Elif Kuzgun ^a   Ozcinar, Evren ^a   Kaya, Bulent ^a   Elhan, Atilla Halil ^a   Ozyurda, Umit ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Biological markers; Cardiopulmonary bypass adverse effects; Flavonoids administration dosage; Hesperidin therapeutic use; Reperfusion injury drug therapy

Indexed keywords

DAFLON; LACTATE DEHYDROGENASE; PLACEBO; TROPONIN I; BIOLOGICAL MARKER; CARDIOTONIC AGENT; DIOSMIN;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; LENGTH OF STAY; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; TREATMENT OUTCOME; BLOOD; CHI SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PREOPERATIVE CARE; TABLET; TIME; TURKEY (REPUBLIC);

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DIOSMIN; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PREOPERATIVE CARE; PROSPECTIVE STUDIES; STROKE VOLUME; TABLETS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I; TURKEY; VENTRICULAR FUNCTION, LEFT;

EID: 77954916691     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Friesenecker B, Tsai AG, Intaglietta M. Cellular basis of inflammation, edema and the activity of Daflon 500 mg. Int J Microcirc Clin Exp 1995;15 Suppl 1:17-21.
2. Meyer O. Safety of use of Daflon 500 mg confirmed by acquired experience and new research. Phlebology 1992;7(Suppl 2):64-8.
3. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999;16(1):9-13.
4. Valen G, Paulsson G, Vaage J. Induction of inflammatory mediators during reperfusion of the human heart. Ann Thorac Surg 2001;71(1):226-32.
5. Sharma M, Ganguly NK, Chaturvedi G, Thingnam SK, Ma-jumdar S, Suri RK. Release of pro-inflammatory mediators during myocardial ischemia/reperfusion in coronary artery bypass graft surgery [published erratum appears in Mol Cell Biochem 2003;251(1-2):169]. Mol Cell Biochem 2003;247(1-2):23-30.
6. Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased mi-crovascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. Angiology 1997;48(5):391-9.
7. Friesenecker B, Tsai AG, Allegra C, Intaglietta M. Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: in vivo observations in the hamster skin fold. Int J Microcirc Clin Exp 1994;14(1-2):50-5.
8. Bouskela E, Cyrino FZ, Lerond L. Leukocyte adhesion after oxidant challenge in the hamster cheek pouch microcircula-tion. J Vasc Res 1999;36 Suppl 1:11-4.
9. Takase S, Delano FA, Lerond L, Bergan JJ, Schmid-Schonbein GW. Inflammation in chronic venous insufficiency. Is the problem insurmountable? J Vasc Res 1999;36 Suppl 1:3-10.
10. Coleridge Smith PD. The microcirculation in venous hypertension. Vasc Med 1997;2(3):203-13.
11. Pickelmann S, Nolte D, Leiderer R, Mollmann M, Schutze E, Messmer K. Effects of the phlebotropic drug Daflon 500 mg on postischemic reperfusion injury in striated skin muscle: a histomorphologic study in the hamster. J Lab Clin Med 1999;134(5):536-45.
12. Korthuis RJ, Gute DC. Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micron-ized purified flavonoid fraction. J Vasc Res 1999;36 Suppl 1:15-23.
13. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996;74(1):86-107.
14. Korthuis RJ, Gute DC. Pathophysiologic implications of leukocyte activation in chronic venous insufficiency. Medico-graphia 2000;22:127-32.
15. Hulstrom D, Svensjo E. Intravital and electron microscopic study of bradykinin-induced vascular permeability changes using FITC-dextran as a tracer. J Pathol 1979;129(3):125-33.
16. Shoab SS, Porter J, Scurr JH, Coleridge-Smith PD. Endothe-lial activation response to oral micronised flavonoid therapy in patients with chronic venous disease--a prospective study. Eur J Vasc Endovasc Surg 1999;17(4):313-8.
17. Lim H, Son KH, Chang HW, Kang SS, Kim HP. Inhibition of chronic skin inflammation by topical anti-inflammatory flavonoid preparation, Ato Formula. Arch Pharm Res 2006;29(6):503-7.
18. Kilicoglu SS, Kilicoglu B, Erdemli E. Ultrastructural view of colon anastomosis under propolis effect by transmission electron microscopy. World J Gastroenterol 2008;14(30):4763-70.
19. Zairis MN, Adamopoulou EN, Manousakis SJ, Lyras AG, Bibis GP, Ampartzidou OS, et al.; Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 2007;194(2):397-402.
20. Westerhout CM, Fu Y, Lauer MS, James S, Armstrong PW, Al-Hattab EA, et al. Short- and long-term risk stratification in acute coronary syndromes. J Am Coll Cardiol 2006;48(5): 939-47.
21. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006; 48(1):1-11.
22. Kupatt C, Habazettl H, Hanusch P, Wichels R, Hahnel D, Becker BF, Boekstegers P. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury. Arterioscler Thromb Vasc Biol 2000;20(10):2226-32.
23. Yavuz T, Altuntas I, Tenekeci C, Kilinc I, Ulusan V, Ocal A, et al. During cardiopulmonary bypass Daflon decreases reperfusion injury by complement inhibition [in Turkish]. Turkish J Thorac Cardiovasc Surg 2004;12:18-21.